Factors Associated With Deprescribing Acetylcholinesterase Inhibitors in Older Nursing Home Residents With Severe Dementia-Reference-Cited by-同舟云学术

Factors Associated With Deprescribing Acetylcholinesterase Inhibitors in Older Nursing Home Residents With Severe Dementia

Published:2019-06-04 Issue:9 Volume:67 Page:1871-1879
ISSN:0002-8614
Container-title:Journal of the American Geriatrics Society
language:en
Short-container-title:J Am Geriatr Soc

Author:

Niznik Joshua D.¹²³^ORCID,Zhao Xinhua¹³,He Meiqi¹,Aspinall Sherrie L.¹³⁴^ORCID,Hanlon Joseph T.²³,Nace David²^ORCID,Thorpe Joshua M.³⁵,Thorpe Carolyn T.³⁵

Affiliation:

1. Department of Pharmacy and Therapeutics University of Pittsburgh School of Pharmacy Pittsburgh Pennsylvania

2. Geriatric Division University of Pittsburgh School of Medicine Pittsburgh Pennsylvania

3. Department of Veterans Affairs Center for Health Equity Research and Promotion VA Pittsburgh Healthcare System Pittsburgh Pennsylvania

4. Department of Veterans Affairs Center for Medication Safety Hines Illinois

5. Department of Pharmaceutical Outcomes and Policy University of North Carolina Eshelman School of Pharmacy Chapel Hill North Carolina

Funder

National Institute on Aging

Patrick and Catherine Weldon Donaghue Medical Research Foundation

Publisher

Wiley

Subject

Geriatrics and Gerontology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgs.15985

Reference56 articles.

1. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study

2. Donepezil preserves cognition and global function in patients with severe Alzheimer disease

3. Donepezil Treatment of Patients with Severe Alzheimer’s Disease in a Japanese Population: Results from a 24-Week, Double-Blind, Placebo-Controlled, Randomized Trial

4. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial

5. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validating claims‐based definitions for deprescribing: Bridging the gap between clinical and administrative data;Pharmacoepidemiology and Drug Safety;2024-03-31

2. Changes in Antidementia Medications upon Admission to the Nursing Home: Who Decides and Why? Results From a National Survey of Nursing Home Administrators;Journal of the American Medical Directors Association;2024-01

3. Antidementia Medication Use in Nursing Home Residents;Journal of Geriatric Psychiatry and Neurology;2023-09-16

4. Deprescribing research in nursing home residents using routinely collected healthcare data: a conceptual framework;BMC Geriatrics;2023-08-04

5. Prescriber Perspectives and Experiences with Deprescribing Versus Continuing Bisphosphonates in Older Nursing Home Residents with Dementia;Journal of General Internal Medicine;2023-06-27